143 related articles for article (PubMed ID: 26123203)
21. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk.
Liu Y; Wang H; Lin T; Wei Q; Zhi Y; Yuan F; Song B; Yang J; Chen Z
Oncol Rep; 2012 Jul; 28(1):337-45. PubMed ID: 22505326
[TBL] [Abstract][Full Text] [Related]
22. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.
Elens L; Sombogaard F; Hesselink DA; van Schaik RH; van Gelder T
Pharmacogenet Genomics; 2013 Dec; 23(12):649-57. PubMed ID: 24113216
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.
Gomes AM; Winter S; Klein K; Turpeinen M; Schaeffeler E; Schwab M; Zanger UM
Pharmacogenomics; 2009 Apr; 10(4):579-99. PubMed ID: 19374516
[TBL] [Abstract][Full Text] [Related]
24. Prostate stem cell antigen rs2294008 (C>T) polymorphism and bladder cancer risk: a meta-analysis based on cases and controls.
Zhao Y; Gui ZL; Liao S; Gao F; Ge YZ; Jia RP
Genet Mol Res; 2014 Jul; 13(3):5534-40. PubMed ID: 25117309
[TBL] [Abstract][Full Text] [Related]
25. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis.
Li C; Wu W; Liu J; Qian L; Li A; Yang K; Wei Q; Zhou J; Zhang Z
Pharmacogenet Genomics; 2006 Apr; 16(4):245-51. PubMed ID: 16538171
[TBL] [Abstract][Full Text] [Related]
26. Exon 3 polymorphisms and haplotypes of O6-methylguanine-DNA methyltransferase and risk of bladder cancer in southern China: a case-control analysis.
Li C; Liu J; Li A; Qian L; Wang X; Wei Q; Zhou J; Zhang Z
Cancer Lett; 2005 Sep; 227(1):49-57. PubMed ID: 15885889
[TBL] [Abstract][Full Text] [Related]
27. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
Stern MC; Johnson LR; Bell DA; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
[TBL] [Abstract][Full Text] [Related]
28. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
29. Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population.
Pandith AA; Shah ZA; Khan NP; Rasool R; Afroze D; Yousuf A; Wani S; Siddiqi M
Cancer Genet Cytogenet; 2010 Dec; 203(2):263-8. PubMed ID: 21156242
[TBL] [Abstract][Full Text] [Related]
30. The association of rs710886 in lncRNA PCAT1 with bladder cancer risk in a Chinese population.
Lin Y; Ge Y; Wang Y; Ma G; Wang X; Liu H; Wang M; Zhang Z; Chu H
Gene; 2017 Sep; 627():226-232. PubMed ID: 28627442
[TBL] [Abstract][Full Text] [Related]
31. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.
Gomes LG; Huang N; Agrawal V; Mendonça BB; Bachega TA; Miller WL
J Clin Endocrinol Metab; 2008 Jul; 93(7):2913-6. PubMed ID: 18397975
[TBL] [Abstract][Full Text] [Related]
32. [Association between genetic polymorphism of UGT1A7 and susceptibility of bladder cancer].
Liu J; Yang XM; Liu G; Chang LS; Zhang LR; Song DK
Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(44):3122-5. PubMed ID: 20193274
[TBL] [Abstract][Full Text] [Related]
33. The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene.
Safarinejad MR; Shafiei N; Safarinejad SH
Arch Toxicol; 2011 Oct; 85(10):1209-18. PubMed ID: 21347663
[TBL] [Abstract][Full Text] [Related]
34. The association between -330T/G polymorphism of interleukin 2 gene and bladder cancer.
Shen Y; Liu Y; Liu S; Zhang A
DNA Cell Biol; 2012 Jun; 31(6):983-7. PubMed ID: 22242968
[TBL] [Abstract][Full Text] [Related]
35. Cumulative effect of genome-wide association study-identified genetic variants for bladder cancer.
Wang M; Chu H; Lv Q; Wang L; Yuan L; Fu G; Tong N; Qin C; Yin C; Zhang Z; Xu J
Int J Cancer; 2014 Dec; 135(11):2653-60. PubMed ID: 24740636
[TBL] [Abstract][Full Text] [Related]
36. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina.
Moore LE; Wiencke JK; Bates MN; Zheng S; Rey OA; Smith AH
Cancer Lett; 2004 Aug; 211(2):199-207. PubMed ID: 15219943
[TBL] [Abstract][Full Text] [Related]
37. Novel SNPs in cytochrome P450 oxidoreductase.
Hart SN; Li Y; Nakamoto K; Wesselman C; Zhong XB
Drug Metab Pharmacokinet; 2007 Aug; 22(4):322-6. PubMed ID: 17827787
[TBL] [Abstract][Full Text] [Related]
38. The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer.
Santos LE; Guilhen AC; de Andrade RA; Sumi LG; Ward LS
Urol Oncol; 2011; 29(3):291-4. PubMed ID: 19523860
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the Association of Eight Polymorphisms with Cancer Susceptibility in a Han Chinese Population.
Dong Y; Chen J; Chen Z; Tian C; Lu H; Ruan J; Yang W
PLoS One; 2015; 10(7):e0132797. PubMed ID: 26176862
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy.
Gong L; Zhang CM; Lv JF; Zhou HH; Fan L
Pharmacogenet Genomics; 2017 Sep; 27(9):337-346. PubMed ID: 28731962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
